Mycobacterial diseases in HIV-positive patients

Journal of Pharmacy Practice

Volumn 19, Issue 1, 2006, Pages 10-16

  Thomas, Dia Jeanette ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Immune reconstitution; Mycobacterium; Opportunistic infection; Prophylaxis; Tuberculosis

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; ATAZANAVIR; AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450 INHIBITOR; DELAVIRDINE; EFAVIRENZ; ETANERCEPT; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; LINEZOLID; LOPINAVIR; MACROLIDE; MOXIFLOXACIN; NEVIRAPINE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; SAQUINAVIR; STREPTOMYCIN; TELITHROMYCIN; TIPRANAVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIUM ISOLATION; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DOSE TIME EFFECT RELATION; DRUG CROSS REACTIVITY; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INFECTION RESISTANCE; INFECTION RISK; LIVER TOXICITY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; POPULATION RESEARCH; PRACTICE GUIDELINE; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

EID: 31144477474     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190005284100     Document Type: Review

References (21)

1. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis. 2003;188:1146-1155.
2. Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2003;52(RR-11):1-88.
3. Small P, Fujiwara P. Management of tuberculosis in the United States. N Engl J Med. 2001;345:189-200.
4. Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151:129-135.
5. Dheda K, Lampe FC, Johnson MA, et al. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004;190:1670-1676.
6. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004;18:257-264.
7. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis. 2004;4:557-565.
8. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons: 2002 recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2002;51(RR-8):1-60.
9. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2004;53(RR-15):1-60.
10. Shafran SD, Mashinter LD, Phillips P, et al. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med. 2002;137:734-737.
11. Aberg JA, Yajko DM, Jacobson MA. Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. Clin Infect Dis. 1998;178:1446-1449.
12. Cinti SK, Kaul DR, Sax PE, et al. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis. 2000;30:511-514.
13. Taillard C, Greub G, Weber R, et al. Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey. J Clin Microbiol. 2003;41:1240-1244.
14. Canueto-Quintero J, Caballero-Granado FJ, Herrero-Romero M, et al. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Clin Infect Dis. 2003;37:584-590.
15. Alcaide F, Calatayud L, Santín M, et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrobial Agents Chemother. 2004;28:4562-4565.
16. Fitzgerald D, Haas D. Mycobacterium tuberculosis. In: Mandell G, Bennett J, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. New York, NY: Churchill Livingstone; 2004.
17. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Rockville, Md: HIV/AIDS Treatment Information Service. Available at: http://AIDSinfo.nih.gov.
18. Tipranavir [package insert]. Ridgefield, Conn: Boehringer-Ingleheim. Available at www.aptivus.com.
19. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19:399-406.
20. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38:1159-1166.
21. Desimone JA, Babinchak TJ, Kaulback KR, et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. AIDS Patient Care STDS. 2003;17:617-622.